Quantcast

Industry news that matters to you.  Learn more

Archives for February 2011

Prize4Life Awards $1 Million Prize for Discovery of ALS Biomarker

Prize4Life, a non-profit organization dedicated to accelerating the discovery of a cure for Amyotrophic Lateral Sclerosis (ALS) by offering incentives to drive innovation, today announced that Dr. Seward Rutkove, Chief of the Division of Neuromuscular Disease at Beth Israel Deaconess Medical Center and Associate Professor of Neurology at Harvard Medical School, has received the $1 million dollar Prize4Life award for the discovery of a new ALS biomarker.

Expression Pathology Provides Roche Biomarker Assay Services for Oncology Drug Development

Expression Pathology recently announced an agreement with Roche to provide its Liquid Tissue-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Vermillion Announces Issuance of Patent for Peripheral Artery Disease

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,867,719 entitled “Beta-2 microglobulin as a biomarker for peripheral artery disease” to the Company. The patent claims are directed to Beta-2 microglobulin and biomarker combinations that include Beta-2 microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay. The studies underlying the patent were conducted with Dr. John P. Cooke, M.D., Ph.D., a Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine. Dr. Cooke is a founder and past President of the Society for Vascular Medicine, and an author of over 350 scientific articles in vascular medicine and biology.

Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers

Avantra Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx BioChip Immunoassay. The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring less than five minutes for sample preparation. Multiplex protein assays can be helpful in evaluating the association between elevated protein levels, patient phenotype and drug response.

Rosetta Genomics Signs Agreements to Advance Development of Body Fluids-Based Diagnostic Tests

Rosetta Genomics has announced that it has signed two new agreements for the development and validation of microRNA-based diagnostics for various indications related to its Gen 3 products. Rosetta Genomics Gen 3 tests focus on cardiovascular indications, neurodegenerative diseases, women’s health and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.